Company Profile

Sentigen Corporation (AKA: Prime Cellular, Inc~Sentigen Holding Corp)
Profile last edited on: 8/20/2018      CAGE: -----      UEI: ----------

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1990
First Award
2002
Latest Award
2002
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3960 Broadway 5th Floor
New York, NY 10032
   (212) 568-6177
   info@sentigen.com
   www.sentigen.com
Location: Single
Congr. District: 13
County: New York

Public Profile

Previously know as In Prime Cellular, in December of 2006, Sentigen Corporation was acquired by Invitrogen Corporation, another SBIR awardee. Sentigen Holding Corp. is a holding company conducting business through two wholly owned operating subsidiaries, Cell & Molecular Technologies, Inc. (CMT) and Sentigen Corp. CMT is comprised of a service organization that provides contract research and development services and a products organization that provides cell culture media, reagents and other research products to companies engaged in the drug discovery process. Sentigen has been engaged in scientific research to develop assays for the screening of G Protein-Coupled Receptors (GPCRs). These assays potentially would have applications in drug discovery, micro-array based detection technologies and environmentally sound pest management solutions for agricultural and human health vectors. CMT specializes in supporting the drug discovery process. CMT's products and services line include high-throughput screening applications, contract research services and the development, production and marketing of specialty cell culture media.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : SGHL
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $100,003
Project Title: Functional Assays of Anopheles Odorant Receptors

Key People / Management

  Joseph Pagano -- President

  Kevin J Lee

  Ron Newbold